Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Common Equity (2018 - 2025)

Silence Therapeutics' Common Equity history spans 8 years, with the latest figure at $62.3 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 53.51% to $62.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.3 million, a 53.51% decrease, with the full-year FY2025 number at $62.3 million, down 53.51% from a year prior.
  • Common Equity hit $62.3 million in Q4 2025 for Silence Therapeutics, down from $74.1 million in the prior quarter.
  • Over the last five years, Common Equity for SLN hit a ceiling of $156.8 million in Q1 2024 and a floor of -$6.0 million in Q2 2022.
  • Historically, Common Equity has averaged $58.8 million across 5 years, with a median of $33.1 million in 2021.
  • Biggest five-year swings in Common Equity: tumbled 118.04% in 2022 and later skyrocketed 829.32% in 2024.
  • Tracing SLN's Common Equity over 5 years: stood at $11.5 million in 2021, then skyrocketed by 125.26% to $25.9 million in 2022, then decreased by 18.26% to $21.2 million in 2023, then skyrocketed by 533.33% to $134.0 million in 2024, then plummeted by 53.51% to $62.3 million in 2025.
  • Business Quant data shows Common Equity for SLN at $62.3 million in Q4 2025, $74.1 million in Q3 2025, and $94.2 million in Q2 2025.